Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study [0.03%]
伊布替尼联合白蛋白结合型紫杉醇和吉西他滨用于转移性胰腺导管腺癌一线治疗：III期RESOLVE研究
M Tempero,D-Y Oh,J Tabernero et al.
M Tempero et al.
Background: First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microe...
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis [0.03%]
科罗拉avin研究：cobimetinib联合化疗，序贯或联用atezolizumab对比医生选择的化疗一线治疗三阴性乳腺癌患者的2期随机试验主要分析结果
A Brufsky,S B Kim,Ž Zvirbule et al.
A Brufsky et al.
Background: Resistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated with upregulation of the mitogen-activated protein kinase (MAPK) pathway. Cobimetinib, an MAPK/extracellula...
High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications [0.03%]
血液系统恶性肿瘤患者中CDA缺乏症高发的启示及治疗意义
M Donnette,J Ciccolini,C Pissier et al.
M Donnette et al.
Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey [0.03%]
法国癌症患者接受SARS-CoV-2疫苗调查
J Barrière,J Gal,B Hoch et al.
J Barrière et al.
Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy [0.03%]
抗雌激素治疗的乳腺癌和卵巢癌患者的SARS-CoV-2感染预后情况
M Montopoli,M Zorzi,V Cocetta et al.
M Montopoli et al.
M Eriksson,H Joensuu
M Eriksson
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC) [0.03%]
特瑞普利单抗或度伐利尤单抗联合化疗对比单纯化疗治疗未接受过免疫检查点抑制剂的晚期/复发性转移性鼻咽癌患者的III期、随机、双盲、安慰剂对照研究
Y Shi,L Wu,X Yu et al.
Y Shi et al.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article was retracted at the request of the authors. The authors of this abstr...
A prospective study of type 2 diabetes, metformin use, and risk of breast cancer [0.03%]
2型糖尿病、双胍类使用与乳腺癌风险的前瞻性研究
Y-M M Park,D B Bookwalter,K M O&#x;Brien et al.
Y-M M Park et al.
Background: Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk. Few studies have investigated T2D and medication...
A E Lohmann,P J Goodwin
A E Lohmann
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA [0.03%]
利用游离DNA甲基化标志物进行敏感和特异的多癌症检测和定位
M C Liu,G R Oxnard,E A Klein et al.
M C Liu et al.
Background: Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performan...